Sanofi Pasteur gains vaccine adjuvants licence
This article was originally published in Scrip
3M Drug Delivery Systems is licensing its patented Toll-like receptor (TLR) agonist compounds to Sanofi Pasteur for use as vaccine adjuvants through a non-exclusive licence agreement. The US company says that its TLR immune response modifier could boost the effectiveness of a vaccine when used as an adjuvant. Unlike most other TLR agonists, which are often much larger and more difficult to manufacture, 3M's compounds, TLR7 and TLR8, are small organically synthesised molecules that give more flexibility in formulation and route of delivery, the company claims. Under the deal, 3M will receive an undisclosed licensing fee, milestones and royalties.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.